Technical Analysis for EXAS - Exact Sciences Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Fell Below 20 DMA | Bearish | -1.38% | |
180 Bearish Setup | Bearish Swing Setup | -1.38% | |
Outside Day | Range Expansion | -1.38% | |
Crossed Above 20 DMA | Bullish | -4.03% | |
Inside Day | Range Contraction | -4.03% | |
20 DMA Resistance | Bearish | -2.23% | |
Gapped Up | Strength | -2.23% | |
Fell Below 20 DMA | Bearish | -3.10% | |
Gapped Down | Weakness | -3.10% |
Alert | Time |
---|---|
Down 3% | about 17 hours ago |
Down 2 % | about 18 hours ago |
60 Minute Opening Range Breakdown | about 18 hours ago |
Bearish 180 Entry | about 18 hours ago |
Fell Below Previous Day's Low | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/19/2025
Exact Sciences Corporation Description
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Medical Test Pancreatic Cancer Lab Testing Colorectal Cancer Inflammatory Bowel Disease Polyp Molecular Diagnostics Cancer Screening Genzyme Mayo Clinic
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 79.62 |
52 Week Low | 40.624 |
Average Volume | 2,095,038 |
200-Day Moving Average | 56.72 |
50-Day Moving Average | 57.63 |
20-Day Moving Average | 54.84 |
10-Day Moving Average | 55.16 |
Average True Range | 2.37 |
RSI (14) | 41.52 |
ADX | 7.3 |
+DI | 16.83 |
-DI | 22.53 |
Chandelier Exit (Long, 3 ATRs) | 53.76 |
Chandelier Exit (Short, 3 ATRs) | 56.91 |
Upper Bollinger Bands | 58.18 |
Lower Bollinger Band | 51.49 |
Percent B (%b) | 0.31 |
BandWidth | 12.21 |
MACD Line | -0.68 |
MACD Signal Line | -0.75 |
MACD Histogram | 0.0618 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 57.20 | ||||
Resistance 3 (R3) | 57.24 | 56.06 | 56.59 | ||
Resistance 2 (R2) | 56.06 | 55.13 | 56.04 | 56.39 | |
Resistance 1 (R1) | 54.80 | 54.55 | 54.20 | 54.75 | 56.18 |
Pivot Point | 53.61 | 53.61 | 53.32 | 53.59 | 53.61 |
Support 1 (S1) | 52.35 | 52.68 | 51.76 | 52.31 | 50.88 |
Support 2 (S2) | 51.16 | 52.10 | 51.14 | 50.67 | |
Support 3 (S3) | 49.90 | 51.16 | 50.47 | ||
Support 4 (S4) | 49.86 |